Enhancement of Th2 responses to replicative herpes simplex virus type 1 vectors by immunomodulative chemotherapy

International Immunopharmacology

Volumn 6, Issue 5, 2006, Pages 817-829

  Peltoniemi, Jutta ^a   Broberg, Eeva K ^a,b   Nygårdas, Michaela ^a   Erälinna, Juha Pekka ^a   Waris, Matti ^a,b   Hukkanen, Veijo ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Cytokines; Gene therapy; Herpes simplex virus; Immunomodulation; Linomide; Vector

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 23; INTERLEUKIN 4; ROQUINIMEX; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COURSE EVALUATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENZYME IMMUNOASSAY; FEMALE; HERPES SIMPLEX VIRUS 1; HERPESVIRUS VECTOR; HOST RESISTANCE; IMMUNOMODULATION; IMMUNOSTIMULATION; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECIES COMPARISON; TH2 CELL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CULTURE; VIRUS LOAD; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BRAIN; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HYDROXYQUINOLINES; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; RNA, MESSENGER; SPLEEN; TH2 CELLS; TRIGEMINAL GANGLION;

EID: 33645029028     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2005.12.003     Document Type: Article

References (46)

1. G. Hedlund, H. Link, J. Zhu, and B.G. Xiao Effects of Linomide on immune cells and cytokines inhibit autoimmune pathologies of the central and peripheral nervous system Int Immunopharmacol 1 2001 1123 1130
2. D.J. Gross, L. Weiss, I. Reibstein, G. Hedlund, E. Dahlen, and M.J. Rapoport The immunomodulator Linomide: role in treatment and prevention of autoimmune diabetes mellitus Int Immunopharmacol 1 2001 1131 1139
3. D. Lehmann, D.M. Karussis, D. Fluresco, R. Mizrachi-Koll, H. Ovadia, and E. Shezen Immunomodulation of autoimmunity by Linomide: inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis J Neuroimmunol 74 1997 102 110
4. E. Dahlen, M. Andersson, K. Dawe, A.C. Tellander, C. Brunmark, and A. Bjork Inhibition of autoimmune disease by the immunomodulator Linomide correlates with the ability to activate macrophages Autoimmunity 32 2000 199 211
5. G. Arad, M. Katzenellenbogen, R. Levy, S. Slavin, and R. Kaempfer Linomide, an immunomodulator that inhibits Th1 cytokine gene expression Int Immunol 8 1996 1603 1607
6. J. Peltoniemi, N. Setälä, E. Broberg, M. Röyttä, V. Hukkanen, and A.A. Salmi Semliki Forest virus infection is enhanced in Th1-prone SJL mice but not in Th2-prone BALB/c mice during Linomide-induced immunomodulation J Neuroimmunol 132 2002 83 92
7. D. Karussis, O. Abramsky, Y. Rosenthal, R. Mizrachi-Koll, and H. Ovadia Linomide downregulates autoimmunity through induction of TH2 cytokine production by lymphocytes Immunol Lett 67 1999 203 208
8. J.P. Erälinna, M. Röyttä, V. Hukkanen, D. Zinhu, A.A. Salmi, and R. Salonen Selective downregulation of Th1 response by Linomide reduces autoimmunity but increases susceptibility to viral infection in BALB/c and SJL mice J Neuroimmunol 88 1998 165 176
9. D.M. Karussis, D. Lehmann, S. Slavin, U. Vourka-Karussis, R. Mizrachi-Koll, and H. Ovadia Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator Linomide Ann Neurol 34 1993 654 660
10. D.M. Karussis, D. Lehmann, S. Slavin, U Vourka-Karussis, R. Mizrachi-Koll, and H. Ovadia Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator Linomide (quinoline-3-carboxamide) Proc Natl Acad Sci U S A 90 1993 6400 6404
11. L. Weiss, V. Barak, M. Zeira, A. Abdul-Hai, I. Raibstein, and S. Reich Cytokine production in Linomide-treated NOD mice and the potential role of a Th (1)/Th(2) shift on autoimmune and anti-inflammatory processes Cytokine 19 2002 85 93
12. A. Abdul-Hai, R. Hershkoviz, L. Weiss, O. Lide, and S. Slavin Effect of Linomide on adhesion molecules, TNF-alpha, nitrogen oxide, and cell adhesion Int Immunopharmacol 5 2005 231 239
13. J. Peltoniemi, E.K. Broberg, A. Halenius, N. Setälä, J.P. Erälinna, and A.A. Salmi Immunomodulation by roquinimex decreases the expression of IL-23(p19) mRNA in the brains of herpes simplex virus type 1 infected BALB/c mice Clin Exp Immunol 137 2004 305 312
14. E.A. Burton, Q. Bai, W.F. Goins, and J.C. Glorioso Replication-defective genomic herpes simplex vectors: design and production Curr Opin Biotechnol 13 2002 424 428
15. - mutant of herpes simplex virus 1 J Virol 71 1997 5560 5569
16. 134.5, a gene nonessential for growth in culture Science 250 1990 1262 1266
17. 134.5 deletion mutants in rodent models J Clin Invest 91 1993 2837 2843
18. J. Markert, M. Medlock, S. Rabkin, G. Gillespie, T. Todo, and W. Hunter Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial Gene Ther 7 2000 867 874
19. R. Rampling, G. Cruickshank, V. Papanastassiou, J. Nicoll, D. Hadley, and D. Brennan Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma Gene Ther 7 2000 859 866
20. V. Papanastassiou, R. Rampling, M. Fraser, R. Petty, D. Hadley, and J. Nicoll The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study Gene Ther 9 2002 398 406
21. S. Harrow, V. Papanastassiou, J. Harland, R. Mabbs, R. Petty, and M. Fraser HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival Gene Ther 11 2004 1648 1658
22. D. Wolfe, A. Niranjan, A. Trichel, C. Wiley, A. Ozuer, and E. Kanal Safety and biodistribution studies of an HSV multigene vector following intracranial delivery to non-human primates Gene Ther 11 2004 1675 1684
23. E. Broberg, N. Setälä, M. Röyttä, J.P. Erälinna, A. Salmi, and B. He Expression of interleukin-4 but not of interleukin-10 from a replicative herpes simplex virus type 1 viral vector precludes experimental allergic encephalomyelitis Gene Ther 8 2001 769 777
24. J. Parker, G.Y. Gillespie, C. Love, S. Randall, R. Whitley, and J.M. Markert Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors Proc Natl Acad Sci U S A 97 2000 2208 2213
25. E.K. Broberg, J. Peltoniemi, M. Nygårdas, T. Vahlberg, M. Röyttä, and V. Hukkanen Spread and replication of and immune response to gamma34.5-negative herpes simplex virus type 1 vectors in BALB/c mice J Virol 78 2004 13139 13152
26. H. Wakimoto, P. Johnson, D. Knipe, and E. Chiocca Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells Gene Ther 10 2003 983 990
27. H. Wakimoto, G. Fulci, E. Tyminski, and E. Antonia-Chiocca Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis Gene Ther 11 2004 214 223
28. P.J. Mabon, L.C. Weaver, and G.A. Dekaban Cyclosporin A reduces the inflammatory response to a multi-mutant herpes simplex virus type-1 leading to improved transgene expression in sympathetic preganglionic neurons in hamsters J Neurovirol 5 1999 268 279
29. M. Lagunoff, and B. Roizman The regulation of synthesis and properties of the protein product of open reading frame P of the herpes simplex virus 1 genome J Virol 69 1995 3615 3623
30. M. Lagunoff, G. Randall, and B. Roizman Phenotypic properties of herpes simplex virus 1 containing a depressed open reading frame P gene J Virol 70 1996 1810 1817
31. S. Andreansky, B. He, J. van Cott, J. McGhee, J. Markert, and G. Gillespie Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins Gene Ther 5 1998 121 130
32. T. Ziegler, M. Waris, M. Rautiainen, and P. Arstila Herpes simplex virus detection by macroscopic reading after overnight incubation and immunoperoxidase staining J Clin Microbiol 26 1988 2013 2017
33. E. Broberg, N. Setälä, J.P. Erälinna, A. Salmi, M. Röyttä, and V. Hukkanen Herpes simplex virus type 1 infection induces upregulation of IL-23 (p19) mRNA expression in trigeminal ganglia of BALB/c mice J Interferon Cytokine Res 22 2002 641 651
34. V. Hukkanen, T. Rehn, R. Kajander, M. Sjöroos, and M. Waris Time-resolved fluorescence (TRF) PCR assay for detection of herpes simplex virus in cerebrospinal fluid J Clin Microbiol 38 2000 3214 3218
35. M. Halminen, P. Klemetti, O. Vaarala, M. Hurme, and J. Ilonen Interferon-gamma production in antigen specific T cell response: quantitation of specific mRNA and secreted protein Scand J Immunol 46 1997 388 392
36. E.K. Broberg, M. Nygårdas, A.A. Salmi, and V. Hukkanen Low copy number detection of herpes simplex virus type 1 mRNA and mouse Th1 type cytokine mRNAs by Light Cycler quantitative real-time PCR J Virol Methods 112 2003 53 65
37. J. Glorioso, and D. Fink Herpes vector-mediated gene transfer in treatment of diseases of the nervous system Annu Rev Microbiol 58 2004 253 271
38. D. Fink, N. DeLuca, W. Goins, and J. Glorioso Gene transfer to neurons using herpes simplex virus-based vectors Annu Rev Neurosci 19 1996 265 287
39. M. Kay, L. Meuse, A. Gown, P. Linsley, D. Hollenbaugh, and A. Aruffo Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver Proc Natl Acad Sci U S A 94 1997 4686 4691
40. S. Kuriyama, K. Tominaga, A. Mitoro, H. Tsujinoue, T. Nakatani, and M. Yamazaki Immunomodulation with FK506 around the time of intravenous re-administration of an adenoviral vector facilitates gene transfer into primed rat liver Int J Cancer 85 2000 839 844
41. K. Ikeda, T. Ichikawa, H. Wakimoto, J. Silver, and T. Deisboeck Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses Nat Med 5 1999 881 887
42. K. Ikeda, H. Wakimoto, T. Ichikawa, S. Jhung, and F. Hochberg Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant J Virol 74 2000 4765 4775
43. B. Oppmann, R. Lesley, B. Blom, J.C. Timans, and Y. Xu Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12 Immunity 13 2000 715 725
44. D.J. Cua, J. Sherlock, Y. Chen, C.A. Murphy, and B. Joyce Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain Nature 421 2003 744 748
45. B. Kwak, F. Mulhaupt, S. Myit, and F. Mach Statins as a newly recognized type of immunomodulator Nat Med 6 2000 1399 1402
46. Y. Zhang, M. Powers, C. Wasserfall, T. Brusko, and S. Song Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity Gene Ther 11 2004 233 240